← Back to patent-cliff list
Clascoterone
Tier C — Watch / tradeClascoterone
Intrepid Therapeutics Inc
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AR
Brand：Winlevi, Breezula
Indications (approved)：Acne vulgaris
Regional status
US
Approved
2020-08-26
EU
Approved
2025-11-17
China
Phase III
2024-05-20
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Clascoterone?
Approved indications include: Acne vulgaris.
When does the Clascoterone patent expire?
No public expiry year is available for Clascoterone yet; this page updates once verified.
How do I get a quote for Clascoterone intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27